Company profile

Sanofi

Immunology + vaccines

SNY · NASDAQ · France

Share price · SNY

$44.97+1.43 (+3.28%) 3M

close as of 2026-08-18 · 24h delayed · vol 3.2M

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Unadjusted for historical splits · Data via Databento

Assets

(37 total)
37Total Assets
14Approved
8Phase 3 / Filed
15Phase 1–2 / Early
18Diseases
Quick filter:
Showing 37 of 37 assets
Target & Modality
Agalsidase beta(Fabrazyme)
Approved
Alpha-galactosidase A (GLA / α-Gal A)Protein / enzyme therapeutic
Chronic Kidney Disease
Approved
CD52Monoclonal antibody
Multiple Sclerosis
Approved
PD-1Monoclonal antibody
Non-Small Cell Lung Cancer
Approved
Microtubules (tubulin)Small molecule
HR+/HER2- Breast Cancer
HR+/HER2- Metastatic Breast Cancer
dupilumab(Dupixent)
Approved
IL-4R-alphaMonoclonal antibody
Atopic DermatitisNon-Small Cell Lung CancerAsthma
insulin glargine(Lantus / Toujeo)
Approved
Insulin receptor (basal)Peptide
Type 2 Diabetes
Approved
Insulin receptor (basal)Peptide
Type 2 Diabetes
Approved
CD38Monoclonal antibody
Multiple Myeloma
lixisenatide(Adlyxin / Lyxumia)
Approved
GLP-1 receptorPeptide
Type 2 Diabetes
Approved
CXCR4Small molecule
Multiple Myeloma
Approved
Insulin receptor (basal)Peptide
Type 2 Diabetes
Approved
IL-6 receptorMonoclonal antibody
Rheumatoid Arthritis
Approved
Dihydroorotate dehydrogenase (DHODH)Small molecule
Multiple Sclerosis
Approved
GABAergic neurotransmissionSmall molecule
Epilepsy
Ciclesonide (XRP1526)No recent activity
Phase 3
Glucocorticoid receptorSmall molecule
Asthma

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Insider transactions

Research

Unlock insider transactions

Research includes SEC Form 4 insider transactions — filed buys, sells, awards and exercises linked to the underlying filings.

Institutional holders

Research

Unlock institutional holders

Research includes quarterly SEC 13F institutional ownership — top holders, aggregate positions and quarter-over-quarter context.